Belumosudil

(Rezurock®)

Belumosudil

Drug updated on 11/27/2023

Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Rezurock (belumosudil) Prescribing Information.2023Kadmon Pharmaceuticals LLC, Warrendale, PA

Randomized Controlled Trials